Repare Therapeutics rises after 'promising' cancer drug data

Repare Therapeutics

11/04/2022 23:10

** Repare Therapeutics' shares  RPTX.O  up 2% at $10.60 in
after-market trade
    ** Reports updated data from early- to mid-stage trial of
cancer drug candidate RP-3500, with "promising results observed
particularly in patients with advanced ovarian cancer"
 urn:newsml:reuters.com:*:nBw8dKKBka
    ** All 10 brokerages covering RPTX rate the stock "buy" or
higher; their median PT is $45
    ** Up to Monday's close, stock had lost about half of its
value YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))